Nanoform
Nanoform is a nanoparticle medicine enabling company that works with pharma partners to reduce attrition in clinical trials and enhance formulation performance of molecules through its nanoforming™ services. Its CESS® technology produces nanoformed™ API particles as small as 10 nm.
headquarters
Nanoform Finland Oyj
Cultivator II
Viikinkaari 4
FI-00790 Helsinki
Finland
Nanoform is a nanoparticle medicine enabling company that works with pharma and biotech partners globally to reduce attrition in clinical trials and enhance the formulation performance of molecules through its nanoforming™ services. The company’s patented and scalable CESS® technology produces nanoformed™ API particles as small as 10 nm. This enables poorly soluble molecules in the drug development pipeline to progress into clinical development by increasing their rate of dissolution , intrinsic solubility, and improving their bioavailability. Nanoform’s technology provides novel opportunities in many value-enhancing drug delivery applications including oral, respiratory and others.
Nanoform shares are publicly traded on the Nasdaq First North Growth Market (Ticker symbol: NANOFH) following an IPO in 2020. The company was founded in 2012, based on technology developed from 2008 at the University of Helsinki, Finland.
